{
  "ptid_time": "123_S_4127_2011-08-03",
  "img_path": "/data/qiuhui/data/adni/images/123_S_4127/2011-08-03/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 25,249 mm³, 13.0% above the reference mean. With a Z-score of 0.33 (62.8th percentile), this represents normal volume ; hippocampal volume measures 8,060 mm³, 4.9% above the reference mean. With a Z-score of 0.55 (70.8th percentile), this represents normal volume ; whole brain volume measures 989,600 mm³, 3.8% below the reference mean. With a Z-score of -0.48 (31.6th percentile), this represents normal volume ; entorhinal cortex volume measures 3,213 mm³, 17.5% below the reference mean. With a Z-score of -1.35 (8.8th percentile), this represents mild atrophy; fusiform gyrus volume measures 16,658 mm³, 8.5% below the reference mean. With a Z-score of -0.96 (16.9th percentile), this represents normal volume ; middle temporal gyrus volume measures 21,216 mm³, 3.4% above the reference mean. With a Z-score of 0.30 (61.9th percentile), this represents normal volume . ",
  "text_data": "Age is 63.1 years. Gender is Female. Education: 16 years. Handedness: Right. Race: White. Medical history: Psychiatric; Neurologic; Dermatologic-Connective Tissue; Musculoskeletal; Allergies or Drug Sensitivities; Major Surgical Procedures. MMSE: 30.0. MoCA: 26.0. Logical Memory: 9.0. Laboratory findings: Vitamin B12: 1059.00 (significant elevated); Serum Uric Acid: 2.40 (significant reduced). APOEε4 alleles: 0.0. Biomarker levels: Florbetapir (AV45): 1.05 SUVR (normal ); Amyloid beta: 744.50 pg/mL (normal ); Total tau: 99.79 pg/mL (moderate reduced); Phosphorylated tau: 8.21 pg/mL (moderate reduced). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The entorhinal cortex shows mild atrophy (Z-score -1.35, 8.8th percentile), which is an early marker of Alzheimer's pathology, but other key regions (hippocampus, whole brain) are within normal ranges. Cognitive scores (MMSE 30, MoCA 26) are borderline for MCI (MoCA <26 is typical for MCI), but biomarkers (normal Aβ, reduced tau) are atypical for AD.  \n**Diagnosis:** **Mild Cognitive Impairment (MCI)**  \n**Confidence:** **Medium** (Atrophy in entorhinal cortex suggests early neurodegeneration, but biomarker profile and preserved cognition complicate a definitive call.)  \n\n**Key Notes:**  \n- **Entorhinal atrophy** is concerning but not severe enough for dementia.  \n- **Normal Aβ** reduces likelihood of AD, but **reduced tau** is unusual (typically elevated in AD).  \n- **MoCA 26** is at the threshold for MCI (often <26), but MMSE 30 is intact.  \n- **APOE4-negative** status and normal AV45 (amyloid PET) further argue against AD.  \n\nAlternative considerations:  \n- **Non-AD neurodegenerative process** (e.g., limbic-predominant age-related TDP-43 encephalopathy [LATE]).  \n- **Vascular or other etiology** if clinical history suggests (though imaging lacks vascular markers).  \n\nWould recommend:  \n- Longitudinal monitoring for cognitive decline.  \n- Further workup if symptoms progress (e.g., FDG-PET, CSF biomarkers).",
  "timestamp": "2025-07-26T12:31:38.945654"
}